Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfamethoxazole is a synthetic sulfonamide antibiotic with broad-spectrum antibacterial activity. It acts as a competitive inhibitor of dihydropteroate synthase, an enzyme involved in the bacterial synthesis of folic acid from para-aminobenzoic acid (PABA). By blocking folic acid production, it inhibits DNA, RNA, and protein synthesis in susceptible bacteria. Sulfamethoxazole is effective against many Gram-positive and Gram-negative bacteria and is commonly used to treat urinary tract infections, respiratory tract infections (such as bronchitis and pneumonia), gastrointestinal infections (including traveler's diarrhea), skin infections caused by Staphylococcus aureus, and Pneumocystis jirovecii pneumonia in immunocompromised patients. It is often combined with trimethoprim for enhanced efficacy but can be used alone for certain indications[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfamethoxazole.